pharma · Metastatic Lung Non-Small Cell Carcinoma · COVID-19 · OTLC
Oncotelic Therapeutics
Onconic Therapeutics is a pharma organization headquartered in Seoul, KR. It trades on NYSE under ticker OTLC. Primary therapeutic focus areas include Metastatic Lung Non-Small Cell Carcinoma, COVID-19, Malignant Pleural
Seoul, KR HQ
2020 Founded
14 Employees
Public company Type
OTLC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Seoul, KR
- Founded
- 2020
- Employees
- 14
- Programs
- 4
- Drugs
- 3
- Patents
- 1
Atezolizumab
Phase 2 · mab · Metastatic Lung Non-Small Cell Carcinoma
Atezolizumab for Metastatic Lung Non-Small Cell Carcinoma is a Phase 2 program (mab) at Oncotelic Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code RG1123580
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Oncotelic Therapeutics
- Phase
- Phase 2
- Modality
- mab
- Indication
- Metastatic Lung Non-Small Cell Carcinoma
- Status
- terminated
- Trials
- 1